SUPERNUS PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $719.0 | $661.8 | $607.5 | $667.2 | $579.8 |
| Operating income | -$62.3 | $81.7 | -$5.3 | $46.1 | $86.0 |
| Net income | -$38.5 | $73.9 | $1.3 | $60.7 | $53.4 |
| Cash Flow Statement | |||||
| Free cash flow | $46.0 | $171.2 | $110.5 | $116.4 | — |
Shares outstanding 58.1M · Free float 80.7%
Annual filing data through FY ended December 31, 2025; float as of September 28, 2026.
Earnings
Other Coverage
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
August 3, 2026
Deals
Supernus Pharmaceuticals to Merge With Indivior Pharmaceuticals in All-Stock Deal
August 3, 2026
Deals
Indivior to Buy Supernus in All-Stock Merger